本研究旨在评估局部治疗 (LT)（包括放疗 (RT) 和细胞减灭性前列腺切除术 (CRP)）在改善寡转移性前列腺癌 (OmPCa) 患者预后方面的疗效。对 PubMed 文章的系统回顾和荟萃分析、Embase 和 Web of Science 于 2010 年至 2023 年 11 月期间发表。该研究包括 11 篇文章，其中包括 3 项随机对照试验 (RCT) 和 8 项回顾性分析。该研究评估了总生存期 (OS)、影像学无进展生存期 (rPFS)、前列腺特异性抗原 (PSA) PFS、癌症特异性生存期 (CSS) 和并发症率 (CR)。LT 组的 OS 显着改善，随机对照试验和非随机对照试验均显示出统计学显着性[风险比(HR) = 0.64； 95% 置信区间 (95% CI)，0.51-0.80； p < 0.0001； HR = 0.55； 95% CI，0.40-0.77； p = 0.0004]。对于 rPFS，RCT 未显示出具有统计学意义的结果（HR = 0.60；95% CI，0.34-1.07；p = 0.09），而非 RCT 则显示出显着结果（HR = 0.42；95% CI，0.24-0.72；p = 0.002）。 RCT 和非 RCT 均显示 PSA-PFS 显着改善（HR = 0.44；95% CI，0.29-0.67；p = 0.0001；HR = 0.51；95% CI，0.32-0.81；p = 0.004）。对于 CSS，RCT 显示出统计差异（HR = 0.65；95% CI，0.47-0.90；p = 0.009），而非 RCT 则没有（HR = 0.61；95% CI，0.29-1.27；p = 0.19）。关于 CR，风险差异为 -0.22（95% CI，-0.32 至 -0.12；p< 0.00001）。LT 显着改善 OmPCa 患者的 OS 和 PFS。需要进一步的随机对照试验来确认这些结果。© 2024 日本泌尿外科协会。

This study aims to evaluate the efficacy of local treatment (LT), including radiotherapy (RT) and cytoreductive prostatectomy (CRP), in improving outcomes for patients with oligometastatic prostate cancer (OmPCa).A systematic review and meta-analysis of articles from PubMed, Embase, and Web of Science published between 2010 and November 2023 were conducted. The study included 11 articles, comprising three randomized controlled trials (RCTs) and eight retrospective analyses. The study assessed overall survival (OS), radiographic progression-free survival (rPFS), prostate-specific antigen (PSA) PFS, cancer-specific survival (CSS), and complication rate (CR).OS was significantly improved in the LT group, with both RCTs and non-RCTs showing statistical significance [hazard ratios (HR) = 0.64; 95% confidence intervals (95% CIs), 0.51-0.80; p < 0.0001; HR = 0.55; 95% CIs, 0.40-0.77; p = 0.0004]. For rPFS, RCTs did not show statistically significant outcomes (HR = 0.60; 95% CIs, 0.34-1.07; p = 0.09), whereas non-RCTs demonstrated significant results (HR = 0.42; 95% CIs, 0.24-0.72; p = 0.002). Both RCTs and non-RCTs showed a significant improvement in PSA-PFS (HR = 0.44; 95%CI, 0.29-0.67; p = 0.0001; HR = 0.51; 95% CIs, 0.32-0.81; p = 0.004). For CSS, RCTs demonstrated statistical differences (HR = 0.65; 95% CIs, 0.47-0.90; p = 0.009), whereas non-RCTs did not (HR = 0.61; 95% CIs, 0.29-1.27; p = 0.19). Regarding CR, the risk difference was -0.22 (95% CIs, -0.32 to -0.12; p < 0.00001).LT significantly improved OS and PFS in patients with OmPCa. Further RCTs are necessary to confirm these results.© 2024 The Japanese Urological Association.